The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

Amendment of regulation 58 (consideration of application)

This adran has no associated Memorandwm Esboniadol

62.—(1) Regulation 58 is amended as follows.

(2) After paragraph (4), insert—

(4A) When considering an application for a UK marketing authorisation, the licensing authority may, if it considers it appropriate, have regard to—

(a)an opinion of the Committee for Medicinal Products for Human Use; or

(b)the results of an assessment of an application for a marketing authorisation by the appropriate authority for the licensing of medicinal products of a country other than the United Kingdom ,

in respect of the medicinal product to which the application relates.

(4B) The licensing authority may under paragraph (4A)—

(a)decide to have regard to the opinions and assessments described in sub-paragraphs (a) and (b) in relation to certain types of medicinal products only; and

(b)determine and publish a list of the countries other than the United Kingdom whose assessments of applications for a marketing authorisation are relevant for the purposes of paragraph (4A)(b)..

(3) Omit paragraphs (6) and (7).